Cantor Fitzgerald Reiterates Overweight Rating for Zevra Therapeutics (NASDAQ:ZVRA)

Cantor Fitzgerald reissued their overweight rating on shares of Zevra Therapeutics (NASDAQ:ZVRA) in a research note released on Wednesday morning,Benzinga reports. They currently have a $25.00 target price on the stock.

A number of other research analysts have also recently commented on the stock. Guggenheim set a $21.00 target price on shares of Zevra Therapeutics and gave the company a “buy” rating in a research report on Tuesday, February 4th. Citigroup reiterated an “outperform” rating on shares of Zevra Therapeutics in a research note on Wednesday. Canaccord Genuity Group cut their price target on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a research note on Thursday, November 14th. Finally, HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Zevra Therapeutics in a research note on Wednesday, November 20th. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $21.71.

Zevra Therapeutics Trading Down 1.9 %

Shares of ZVRA stock opened at $7.92 on Wednesday. The company’s 50-day moving average price is $7.95 and its 200-day moving average price is $8.14. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.84. The stock has a market cap of $422.74 million, a price-to-earnings ratio of -4.02 and a beta of 1.98. Zevra Therapeutics has a twelve month low of $4.20 and a twelve month high of $9.76.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its earnings results on Tuesday, March 11th. The company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.28). Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. The company had revenue of $12.00 million during the quarter, compared to analyst estimates of $8.93 million. As a group, equities analysts predict that Zevra Therapeutics will post -1.95 earnings per share for the current year.

Insider Buying and Selling

In other Zevra Therapeutics news, CEO Neil F. Mcfarlane sold 61,273 shares of the stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total value of $481,605.78. Following the transaction, the chief executive officer now directly owns 222,060 shares in the company, valued at $1,745,391.60. This represents a 21.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO R. Laduane Clifton sold 11,000 shares of the stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total transaction of $86,460.00. Following the completion of the transaction, the chief financial officer now owns 51,361 shares in the company, valued at $403,697.46. This represents a 17.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 85,773 shares of company stock worth $674,176. Company insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On Zevra Therapeutics

Several hedge funds have recently added to or reduced their stakes in the stock. MetLife Investment Management LLC increased its stake in Zevra Therapeutics by 8.1% in the third quarter. MetLife Investment Management LLC now owns 22,866 shares of the company’s stock valued at $159,000 after purchasing an additional 1,717 shares during the last quarter. IFG Advisors LLC boosted its holdings in shares of Zevra Therapeutics by 10.0% in the fourth quarter. IFG Advisors LLC now owns 29,050 shares of the company’s stock valued at $242,000 after acquiring an additional 2,650 shares during the period. Invesco Ltd. boosted its holdings in shares of Zevra Therapeutics by 19.6% in the fourth quarter. Invesco Ltd. now owns 18,384 shares of the company’s stock valued at $153,000 after acquiring an additional 3,007 shares during the period. Corebridge Financial Inc. boosted its holdings in shares of Zevra Therapeutics by 16.9% in the fourth quarter. Corebridge Financial Inc. now owns 26,294 shares of the company’s stock valued at $219,000 after acquiring an additional 3,801 shares during the period. Finally, Squarepoint Ops LLC boosted its holdings in shares of Zevra Therapeutics by 36.1% in the fourth quarter. Squarepoint Ops LLC now owns 16,534 shares of the company’s stock valued at $138,000 after acquiring an additional 4,384 shares during the period. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.